|
Recent Developments |
|
22-JAN-16
Sun Pharmaceutical Industries announced that the company has received order under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transactio
16-NOV-15
Shasun Pharmaceuticals, a pharmaceutical contracting organization, today announced that it has received approval from the United States Food & Drug Administration (USFDA) for Carisoprodol Tablets USP 250 mg and 350 mg.
23-JUL-15
Shasun P... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Shasun Chemicals and Drugs Ltd, while focusing on the bulk drugs business, expects increased contribution from the contract research business. The bulk drugs business, including the biotech sector, will continue to be its major focus in the years to come. S. Vimal Kumar |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 30-Sep-2015(6) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 5020.60 | 10243.10 | 8816.20 | | Other Income | 59.10 | 139.20 | 122.70 | | Total Income | 5079.70 | 10382.30 | 8938.90 | | Cost of goods sold | 4679.70 | 9655.00 | 8452.70 | | OPBDIT | 400.00 | 727.30 | 486.20 | | PAT | 187.20 | 413.40 | 352.30 | | Gross Block | - | - | - | | Equity capital | 134.50 | 120.30 | 113.30 | | EPS (Rs.) | - | 6.94 | 6.22 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 10.12 - 56.41 | 7.33 - 15.14 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 7.9 | 7.0 | 5.4 | | Net margin (% of OI) | 3.7 | 4.0 | 3.9 |
|
|
Detailed Financials
|
|
|
|
|
